This trial is evaluating whether Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) will improve 1 primary outcome and 5 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of 2 years.
This trial requires 29 total participants across 1 different treatment group
This trial involves a single treatment. Endobronchial Ultrasound-guided Transbronchial Fine Needle Aspiration (EBUS-TFNA) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Carcinoma, non-small-cell lung can be cured--but in our patients with advanced disease--survivors have significant morbidity. To date, only 3 randomized controlled trials in advanced disease have demonstrated a survival difference, which makes cure an elusive goal for many patients." - Anonymous Online Contributor
"CNCI and CC are two separate but morphologically similar malignancies. Both CNCI and CC exhibit a strong tendency towards metastasis. CNCI and CC are both highly curable by chemotherapy alone. Because of this strong tendency for metastasis, CNCI and CC are treated as a single entity, with a corresponding change in treatment guidelines." - Anonymous Online Contributor
"In a recent study, findings most cases of NSCLC were diagnosed in smokers, but cigarette smoking was not the only factor for development of the tumors. Cigarette smoking is the most common cause of NSCLC in developed countries, but its contribution to the carcinogenicity of other environmental carcinogens in this cancer is not clear." - Anonymous Online Contributor
"There are multiple options for treatment of carcinoma, non-small-cell lung, including surgery, radiation therapy, chemotherapy, and targeted therapies. Surgery often offers the only option. Radiation therapy may help shrink the size and growth of the tumor and can have a longer term effect on survival. Chemotherapy often helps control or slow the spread of cancer after it has been detected. Targeted therapies provide a more specific mode of action. Some cancer treatments are being tested for a future role in treatment. In many cases specific clinical trials are testing these potential drugs." - Anonymous Online Contributor
"In the present study, 1 in 60 men was diagnosed with NSCLC, with the rate increasing with age. Overall, the incidence of NSCLC was greater in blacks versus whites and in men who were current smokers." - Anonymous Online Contributor
"It is the author's opinion that most of the signs listed in this article may be useful to improve the clinical diagnosis of carcinoma, non-small-cell lung." - Anonymous Online Contributor
"In the United States, the most common forms of cancer, lung cancer and pancreatic cancer, are now both due to tobacco, but the proportion of all cancers due to any single factor has declined. The proportion due to alcohol has increased by a small amount. While this is a small change, if the proportion of deaths caused by cancer is to be reduced in the future, these changes in the distribution of factors in cancer will be important. The current trends are likely to affect the number of new cases of cancer, and the rate of cancer cases among current smokers. There is a risk of increasing the rates of cancers associated with second-hand smoke. However, the rates of disease associated with occupational factors are likely to decrease." - Anonymous Online Contributor
"The risk of pneumonia following endobronchial ultrasound-guided transbronchial fine needle aspiration of the lung is less than previous estimates and similar across all age groups, with a low false-negative rate and excellent specificity but low sensitivity." - Anonymous Online Contributor
"The overall response rate for the pooled chemotherapy and/or radiotherapy regimens combined with chemotherapy was 67.2% (58.6% in EGFR positive; 81.4% in EGFR negative); and 43% (33.05% in EGFR positive; 45.11% in EGFR negative), which is reasonable for the standard of clinical practice. The response rate for the pooled chemotherapy and/or radiotherapy regimens combined with chemotherapy was 50.4% (52.6% in EGFR positive; 45.7% in EGFR negative); and 36.7% (31.5% in EGFR positive; 40.1% in EGFR negative), which is reasonable for clinical practice." - Anonymous Online Contributor
"BNFNA with EUS imaging alone was able to obtain sufficient cellularity in a high proportion of patients with cancer. This is likely due to ultrasound image-guided localization of the lesion which is thought to reduce the risk of tracheobronchial tree perforation due to EUS ultrasound. In addition, EUS guided aspiration of small lesions in the trachea is feasible and useful in achieving cytological diagnostic adequacy in an endoscopic, ambulatory setting." - Anonymous Online Contributor
"There is a recent development in ebus-tfna for therapeutic use, which is used by clinicians and pathologists to diagnose malignancy at early stages, such as cancers of the lung, oesophagus, and liver. Its potential is as yet to be fully understood." - Anonymous Online Contributor
"The patients with moderate and severe symptoms can be treated by EUS-TFNA without worsening the quality of life. As we found a trend toward a greater response with EUS-TFNA compared to EUS, we feel EUS-TFNA can be used as part of the diagnostic workup." - Anonymous Online Contributor